Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer

M. Merlano, A. Grimaldi, M. Benasso, A. Bacigalupo, S. Toma, D. Scarpati, R. Corvo, A. Santelli, G. Garaventa, R. Rosso

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Thirty-four patients with advanced (stage IV) or relapsing squamous cell carcinoma of the head and neck (SCC-HN) were treated alternately with chemotherapy (CT) and radiotherapy (RT). Patients' characteristics were as follows: male:female ratio, 27:7; median age, 55 (34-76), median P.S., 1 (ECOG scale) (range 0-2). Patients studied had no renal, hepatic, or cardiac impairments, a life expectancy of ≥3 months, and no previous treatment with RT of CT. Seventeen patients were previously untreated, and 17 had a relapse after radical surgery. The CT regimen consisted of 20 mg/m2 cisplatin, with 2 h forced diuresis, from day 1 to 5, and 200 mg/m2 i.v., from day 1 to 5, every 3 weeks, administered four times. The RT was performed after the first, second, and third CT course, and consisted of three courses of 20 Gy each, 2 Gy daily, 5 days per week. Weekend intervals were planned between CT and RT treatments. The 17 previously untreated patients showed an overall response rate of 88.2% [eight complete response (CR), seven partial response (PR), one stable disease (SD), one progression disease (PD)]; the 17 patients treated at relapse after radical surgery reached an overall response rate of 64.7% (six CR, five PR, six PD). Actuarial median survival is 47 weeks: 51 weeks in intreated patients, and 42 weeks in previously treated patients. Toxicity was mild, and only 10 patients suffered from grade III (WHO scale) gastrointestinal (2 patients), hematological (5 patients), mucosal (2 patients), and neurological (1 patient) toxicity. Neither grade IV toxicity nor treatment-related deaths have been observed. In our study, cisplatin and 5-FU alternating with RT has shown an interesting antitumor activity and moderate side effects.

Original languageEnglish
Pages (from-to)538-542
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume11
Issue number5
Publication statusPublished - 1988

Fingerprint

Head and Neck Neoplasms
Fluorouracil
Cisplatin
Radiotherapy
Drug Therapy
Disease Progression
Recurrence
Diuresis
Life Expectancy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Merlano, M., Grimaldi, A., Benasso, M., Bacigalupo, A., Toma, S., Scarpati, D., ... Rosso, R. (1988). Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 11(5), 538-542.

Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. / Merlano, M.; Grimaldi, A.; Benasso, M.; Bacigalupo, A.; Toma, S.; Scarpati, D.; Corvo, R.; Santelli, A.; Garaventa, G.; Rosso, R.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 11, No. 5, 1988, p. 538-542.

Research output: Contribution to journalArticle

Merlano, M, Grimaldi, A, Benasso, M, Bacigalupo, A, Toma, S, Scarpati, D, Corvo, R, Santelli, A, Garaventa, G & Rosso, R 1988, 'Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 11, no. 5, pp. 538-542.
Merlano, M. ; Grimaldi, A. ; Benasso, M. ; Bacigalupo, A. ; Toma, S. ; Scarpati, D. ; Corvo, R. ; Santelli, A. ; Garaventa, G. ; Rosso, R. / Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1988 ; Vol. 11, No. 5. pp. 538-542.
@article{c20e3ad9642f48d8a70e95aa379ff092,
title = "Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer",
abstract = "Thirty-four patients with advanced (stage IV) or relapsing squamous cell carcinoma of the head and neck (SCC-HN) were treated alternately with chemotherapy (CT) and radiotherapy (RT). Patients' characteristics were as follows: male:female ratio, 27:7; median age, 55 (34-76), median P.S., 1 (ECOG scale) (range 0-2). Patients studied had no renal, hepatic, or cardiac impairments, a life expectancy of ≥3 months, and no previous treatment with RT of CT. Seventeen patients were previously untreated, and 17 had a relapse after radical surgery. The CT regimen consisted of 20 mg/m2 cisplatin, with 2 h forced diuresis, from day 1 to 5, and 200 mg/m2 i.v., from day 1 to 5, every 3 weeks, administered four times. The RT was performed after the first, second, and third CT course, and consisted of three courses of 20 Gy each, 2 Gy daily, 5 days per week. Weekend intervals were planned between CT and RT treatments. The 17 previously untreated patients showed an overall response rate of 88.2{\%} [eight complete response (CR), seven partial response (PR), one stable disease (SD), one progression disease (PD)]; the 17 patients treated at relapse after radical surgery reached an overall response rate of 64.7{\%} (six CR, five PR, six PD). Actuarial median survival is 47 weeks: 51 weeks in intreated patients, and 42 weeks in previously treated patients. Toxicity was mild, and only 10 patients suffered from grade III (WHO scale) gastrointestinal (2 patients), hematological (5 patients), mucosal (2 patients), and neurological (1 patient) toxicity. Neither grade IV toxicity nor treatment-related deaths have been observed. In our study, cisplatin and 5-FU alternating with RT has shown an interesting antitumor activity and moderate side effects.",
author = "M. Merlano and A. Grimaldi and M. Benasso and A. Bacigalupo and S. Toma and D. Scarpati and R. Corvo and A. Santelli and G. Garaventa and R. Rosso",
year = "1988",
language = "English",
volume = "11",
pages = "538--542",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer

AU - Merlano, M.

AU - Grimaldi, A.

AU - Benasso, M.

AU - Bacigalupo, A.

AU - Toma, S.

AU - Scarpati, D.

AU - Corvo, R.

AU - Santelli, A.

AU - Garaventa, G.

AU - Rosso, R.

PY - 1988

Y1 - 1988

N2 - Thirty-four patients with advanced (stage IV) or relapsing squamous cell carcinoma of the head and neck (SCC-HN) were treated alternately with chemotherapy (CT) and radiotherapy (RT). Patients' characteristics were as follows: male:female ratio, 27:7; median age, 55 (34-76), median P.S., 1 (ECOG scale) (range 0-2). Patients studied had no renal, hepatic, or cardiac impairments, a life expectancy of ≥3 months, and no previous treatment with RT of CT. Seventeen patients were previously untreated, and 17 had a relapse after radical surgery. The CT regimen consisted of 20 mg/m2 cisplatin, with 2 h forced diuresis, from day 1 to 5, and 200 mg/m2 i.v., from day 1 to 5, every 3 weeks, administered four times. The RT was performed after the first, second, and third CT course, and consisted of three courses of 20 Gy each, 2 Gy daily, 5 days per week. Weekend intervals were planned between CT and RT treatments. The 17 previously untreated patients showed an overall response rate of 88.2% [eight complete response (CR), seven partial response (PR), one stable disease (SD), one progression disease (PD)]; the 17 patients treated at relapse after radical surgery reached an overall response rate of 64.7% (six CR, five PR, six PD). Actuarial median survival is 47 weeks: 51 weeks in intreated patients, and 42 weeks in previously treated patients. Toxicity was mild, and only 10 patients suffered from grade III (WHO scale) gastrointestinal (2 patients), hematological (5 patients), mucosal (2 patients), and neurological (1 patient) toxicity. Neither grade IV toxicity nor treatment-related deaths have been observed. In our study, cisplatin and 5-FU alternating with RT has shown an interesting antitumor activity and moderate side effects.

AB - Thirty-four patients with advanced (stage IV) or relapsing squamous cell carcinoma of the head and neck (SCC-HN) were treated alternately with chemotherapy (CT) and radiotherapy (RT). Patients' characteristics were as follows: male:female ratio, 27:7; median age, 55 (34-76), median P.S., 1 (ECOG scale) (range 0-2). Patients studied had no renal, hepatic, or cardiac impairments, a life expectancy of ≥3 months, and no previous treatment with RT of CT. Seventeen patients were previously untreated, and 17 had a relapse after radical surgery. The CT regimen consisted of 20 mg/m2 cisplatin, with 2 h forced diuresis, from day 1 to 5, and 200 mg/m2 i.v., from day 1 to 5, every 3 weeks, administered four times. The RT was performed after the first, second, and third CT course, and consisted of three courses of 20 Gy each, 2 Gy daily, 5 days per week. Weekend intervals were planned between CT and RT treatments. The 17 previously untreated patients showed an overall response rate of 88.2% [eight complete response (CR), seven partial response (PR), one stable disease (SD), one progression disease (PD)]; the 17 patients treated at relapse after radical surgery reached an overall response rate of 64.7% (six CR, five PR, six PD). Actuarial median survival is 47 weeks: 51 weeks in intreated patients, and 42 weeks in previously treated patients. Toxicity was mild, and only 10 patients suffered from grade III (WHO scale) gastrointestinal (2 patients), hematological (5 patients), mucosal (2 patients), and neurological (1 patient) toxicity. Neither grade IV toxicity nor treatment-related deaths have been observed. In our study, cisplatin and 5-FU alternating with RT has shown an interesting antitumor activity and moderate side effects.

UR - http://www.scopus.com/inward/record.url?scp=0023784105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023784105&partnerID=8YFLogxK

M3 - Article

C2 - 3177255

AN - SCOPUS:0023784105

VL - 11

SP - 538

EP - 542

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -